Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies

Statistics in Medicine

Volumn 35, Issue 19, 2016, Pages 3285-3302

  Fu, Haoda ^a   Zhou, Jin ^b   Faries, Douglas E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

multiple treatments; observational studies; personalized medicine; randomized control trials; subgroup identification; value function

Indexed keywords

BIOLOGICAL MARKER; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE;

ALGORITHM; ARTICLE; DATA ANALYSIS; HUMAN; MATHEMATICAL COMPUTING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT SELECTION; PERSONALIZED MEDICINE; RANDOM SAMPLE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION;

EID: 84977634231     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6920     Document Type: Article

References (36)

1. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. Aaps Pharmsci. 2000; 2(1): 29–41.
2. American Diabetes Association and others. Standards of medical care in diabetes 2014. Diabetes Care. 2014; 37(Supplement 1): S14–S80.
3. Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics Era. Current Genomics. 2010; 11(3): 146–161.
4. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Journal of Clinical Oncology. 2007; 25(23): 3525–3533.
5. Shuldiner AR, OConnell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson, Q,. et al. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama. 2009; 302(8): 849–857.
6. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology. 2004; 57(3): 229–236.
7. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. New England Journal of Medicine. 2006; 354(16): 1667.
8. Ruberg SJ, Chen L, Wang Y. The mean does not mean as much anymore: finding sub-groups for tailored therapeutics. Clinical Trials. 2010; 7(5): 574–583.
9. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet. 2005; 365(9454): 176–186.
10. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine?reporting of subgroup analyses in clinical trials. New England Journal of Medicine. 2007; 357(21): 2189–2194.
11. Su X, Tsai CL, Wang H, Nickerson DM, Li B. Subgroup analysis via recursive partitioning. The Journal of Machine Learning Research. 2009; 10: 141–158.
12. Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search a recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine. 2011; 30(21): 2601–2621.
13. Doove LL, Dusseldorp E, Van Deun K, Van Mechelen I. A comparison of five recursive partitioning methods to find person subgroups involved in meaningful treatment—subgroup interactions. Advances in Data Analysis and Classification. 2014; 8(4): 403–425.
14. Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011; 12(2): 270–282.
15. Zhao L, Tian L, Cai T, Claggett B, Wei LJ. Effectively selecting a target population for a future comparative study. Journal of the American Statistical Association. 2013; 108(502): 527–539.
16. Foster JC, Taylor JM, Ruberg SJ. Subgroup identification from randomized clinical trial data. Statistics in Medicine. 2011; 30(24): 2867–2880.
17. Faries DE, Chen Y, Lipkovich I, Zagar A, Liu X, Obenchain RL. Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder. International Journal of Methods in Psychiatric Research. 2013; 22: 185–194.
18. Qian M, Murphy SA. Performance guarantees for individualized treatment rules. Annals of Statistics. 2011; 39(2): 1180–1210.
19. Zhao Y, Zeng D, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. Journal of the American Statistical Association. 2012; 107(499): 1106–1118.
20. Zhang B, Tsiatis AA, Laber EB, Davidian M. A robust method for estimating optimal treatment regimes. Biometrics. 2012; 68(4): 1010–1018.
21. Zhang B, Tsiatis AA, Davidian M, Zhang M, Laber E. Estimating optimal treatment regimes from a classification perspective. Statistic. 2012; 1(1): 103–114.
22. Xu Y, Yu M, Zhao YQ, Li Q, Wang S, Shao J. Regularized outcome weighted subgroup identification for differential treatment effects. Biometrics. 2015; 71(3): 645–653.
23. Foster JC, Taylor JM, Kaciroti N, Nan B. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data. Biostatistics. 2015; 16(2): 368–382.
24. Su X, Kang J, Fan J, Levine RA, Yan X. Facilitating score and causal inference trees for large observational studies. The Journal of Machine Learning Research. 2012; 13(1): 2955–2994.
25. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70(1): 41–55.
26. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. Journal of the American Statistical Association. 1952; 47(260): 663–685.
27. Robins JM, Rotnitzky A. Recovery of information and adjustment for dependent censoring using surrogate markers. Aids Epidemiology, Methodological issues. 1992; 3: 297–331.
28. Murphy SA. A generalization error for q-learning. Journal of Machine Learning Research: JMLR. 2005; 6: 1073–1097.
29. Zhao Y, Zeng D. Recent development on statistical methods for personalized medicine discovery. Frontiers of Medicine. 2013; 7(1): 102–110.
30. Liu Y, Wang Y, Kosorok M, Zhao Y, Zeng D. Robust hybrid learning for estimating personalized dynamic treatment regimes. Manuscript under Review. 2014.
31. R Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing: Vienna, Austria, 2014.
32. Eddelbuettel D, François R, Allaire J, Chambers J, Bates D, Ushey K. Rcpp: Seamless r and c++ integration. Journal of Statistical Software. 2011; 40(8): 1–18.
33. Hastie TJ, Tibshirani RJ, Friedman JH. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer: New York, NY, USA, 2011.
34. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabetic Medicine. 2005; 22(4): 399–405.
35. Kehl V, Ulm K. Responder identification in clinical trials with censored data. Computational Statistics & Data Analysis. 2006; 50(5): 1338–1355.
36. Chen G, Zhong H, Belousov A, Devanarayan V. A prim approach to predictive-signature development for patient stratification. Statistics in Medicine. 2015; 34(2): 317–342.